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International travel is considered to be an impor-
tant risk factor for acquisition of multidrug-resistant 
Enterobacteriaceae (MRE). The aim of this system-
atic review was to determine the effect of interna-
tional travel on the risk of post-travel faecal carriage 
of MRE. Secondary outcomes were risk factors for 
acquisition of MRE. A systematic search for relevant 
literature in seven international databases was con-
ducted according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines. Articles needed to report on (i) foreign 
travel, (ii) screening of asymptomatic participants, 
(iii) antimicrobial susceptibility data and (iv) faecal 
Enterobacteriaceae carriage. Two researchers inde-
pendently screened the abstracts, assessed the full 
article texts for eligibility and selected or rejected 
them for inclusion in the systematic review. In case of 
disagreement, a third researcher decided on inclusion. 
Eleven studies were identified. In all studies, a high 
prevalence (>  20%) of carriage of MRE after interna-
tional travel was found. The highest prevalence was 
observed in travellers returning from southern Asia. 
Foreign travel was associated with an increased risk of 
carriage of MRE. Further research is needed to assess 
if this leads to an increase in the number of infections 
with MRE. Systematic review registration number: 
PROSPERO CRD42015024973.
Introduction
Rationale
Worldwide, the number of international travellers has 
grown from 25 million in 1950 to 1,087 million in 2013 
[1]. According to the World Tourism Organization, this 
number is expected to increase by an average of 3.3% 
a year [1]. Of the international travellers visiting devel-
oping countries, 22–64% have self-reported health 
problems and about 8% require medical care during 
or after travel [2,3]. Healthy travellers may be exposed 
to a broad range of microorganisms while travelling, 
including drug-resistant Enterobacteriaceae, which may 
subsequently be introduced into their home country 
[4,5].
Enterobacteriaceae are Gram-negative bacteria that are 
part of the human body’s normal commensal flora, called 
microbiota. Enterobacteriaceae, such as Escherichia 
coli and Klebsiella species, are capable of causing both 
healthcare-associated and community-acquired infec-
tions [6]. Multidrug-resistant Enterobacteriaceae (MRE), 
including extended-spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae (ESBL-E) and plasmid-
mediated Amp C-producing Enterobacteriaceae (pAmp 
C-E) are emerging worldwide [7]. Cases of carbapen-
emase-producing Enterobacteriaceae (CPE) are also 
reported more frequently [8]. 
Since 2003, community carriage rates of MRE have 
increased dramatically in various regions, such as 
South-East Asia, the Western Pacific and the Eastern 
Mediterranean [7]. During visits to such areas, travel-
lers might acquire MRE and become asymptomatic car-
riers of MRE. In their home country, they may cause 
spread in the community and contribute to worldwide 
emerging antimicrobial resistance [6,9,10]. Acquired 
MRE in the digestive tract are considered apatho-
genic, however carriage of such Enterobacteriaceae 
have resulted in clinically relevant infections [8]. 
International travel has been reported as a risk factor 
for urinary tract infections caused by ESBL-E [11,12]. 
The question arises if these observations warrant clini-
cians being aware of MRE in recently returned other-
wise healthy, international travellers who seek medical 
attention even for unrelated conditions.
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Figure
Flowchart for literature search on the acquisition of multidrug-resistant Enterobacteriaceae in international travel 
(n = 4,989)
 Articles identified in Embase, 
MEDLINE, Web of Science, Scopus, 
The Cochrane Library, PubMed and 
Google Scholar
(n=5,189)
Articles identified by 
searching references in 
published articles 
(n=0)
Articles screened 
(n=2,398)
Duplicates removed
(n=2,791)
Articles not eligible based 
on title and/or abstract 
(n=2,362)
Articles retrieved for 
further evaluation 
(n=36)
Articles included in 
systematic review 
(n=11)
Studies excluded for the following reasons (n=25):
Letter to the editor (n=2)
Review (n=4)
Study design (n=1)
Oral or poster presentation (3)
No ESBL-Enterobacteriaceae (n=6)
Symptomatic patients (n=7)
No travel (n=1)
Results of a follow-up study (n=1)
ESBL: extended-spectrum beta-lactamase.
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Objectives
The aim of this systematic review was to determine 
the effect of international travel on the risk of acquisi-
tion of faecal carriage of MRE. A secondary objective 
was to determine risk factors for acquisition of drug 
resistance.
Methods
Protocol and registration
A specific protocol was designed and used to conduct 
the study. The study is registered in the international 
prospective register of systematic reviews (PROSPERO) 
under registration number CRD42015024973.
Search strategy and selection criteria
The systematic review was conducted according to 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [13]. The following 
databases were searched, attempting to identify all 
relevant studies: Embase, MEDLINE, Web of Science, 
Scopus, Cochrane Library, PubMed and Google Scholar. 
The latest search was conducted on 17 August 2015.
The topic search terms used for searching the data-
bases were ‘Gram negative bacteria’, ‘Gram negative 
bacterial infections’, ‘Enterobacteriaceae’, ‘Escherichia’, 
‘Klebsiella’, ‘Campylobacter’, ‘Salmonella’, ‘Shigella’, 
’Yersinia’, ‘travel’, ‘traveller’, ‘tourist’, ‘tourism’, 
‘turista’, ‘aviation’, ‘air transport’, ‘airport’, ‘colonisa-
tion’, ‘carriage’, ‘carrier’, ‘susceptibility’ and ‘(multiple) 
drug resistance’.
The queries differed per database searched and were 
developed with help of a biomedical information spe-
cialist (Box). Articles written in English, German, French 
and Dutch were included. 
For inclusion the article needed to fulfil the following 
criteria [1]: It needed to be related to foreign travel [2], 
report on screening in asymptomatic participants [3], 
present antimicrobial susceptibility data and [4] report 
on faecal Enterobacteriaceae carriage. We used the fol-
lowing exclusion criteria: case reports, reviews, meta-
analyses, veterinary medicine, in vitro studies and 
studies regarding symptomatic patients. The reference 
lists of reviews were screened to identify studies pos-
sibly missed by the search.
Two researchers (R.H. and J.A.) independently per-
formed the screening of the abstracts. Any discord-
ant result was discussed in consensus meetings. After 
Box
Search strategy for systematic review of the acquisition of multidrug-resistant Enterobacteriaceae in international travel
Embase.com (‘Gram negative bacterium’/exp OR ‘Gram negative infection’/de OR Enterobacteriaceae/de OR Escherichia/exp OR 
Klebsiella/exp OR Salmonella/exp OR Shigella/exp OR Yersinia/exp OR ‘Enterobacteriaceae infection’/exp OR (‘Gram negative’ OR 
Enterobacteri* OR (Enter* NEXT/1 bacteria*) OR Enterobacter* OR Escherichia* OR ‘e coli’ OR Klebsiella* OR Salmonell* OR Shigell* 
OR Yersinia*):ab,ti) AND (travel/de OR ‘traveller diarrhoea’/de OR aviation/exp OR (travel* OR touris* OR turista OR aviation OR ‘air 
transport’ OR airport*):ab,ti) AND (‘antibiotic resistance’/exp OR ‘multidrug resistance’/de OR ‘drug resistance’/de OR ‘antibiotic 
sensitivity’/de OR ‘bacterial colonization’/exp OR ‘bacterium carrier’/de OR (resistan* OR coloni* OR ((antibiotic* OR antimicrob*) 
NEAR/3 sensitivit*) OR susceptib* OR carriage* OR carrier*):ab,ti) NOT ([animals]/lim NOT [humans]/lim)
MEDLINE (OvidSP) (exp “Gram-Negative Bacteria”/ OR exp “Gram-Negative Bacterial Infections”/ OR Enterobacteriaceae/ OR exp 
Escherichia/ OR exp Klebsiella/ OR exp Salmonella/ OR exp Shigella/ OR exp Yersinia/ OR exp “Enterobacteriaceae infections”/ 
OR (“Gram negative” OR Enterobacteri* OR (Enter* ADJ bacteria*) OR Enterobacter* OR Escherichia* OR “e coli” OR Klebsiella* OR 
Salmonell* OR Shigell* OR Yersinia*).ab,ti.) AND (travel/ OR “Travel Medicine”/ OR exp aviation/ OR (travel* OR touris* OR turista OR 
aviation OR “air transport” OR airport*).ab,ti.) AND (exp “Drug Resistance, Microbial”/ OR exp “Drug Resistance, Multiple”/ OR “drug 
resistance”/ OR “bacterium carrier”/ OR (resistan* OR coloni* OR ((antibiotic* OR antimicrob*) ADJ3 sensitivit*) OR susceptib* OR 
carriage* OR carrier*).ab,ti.) NOT (exp animals/ NOT humans/)
Cochrane Library ((‘Gram negative’ OR Enterobacteri* OR (Enter* NEXT/1 bacteria*) OR Enterobacter* OR Escherichia* OR ‘e coli’ 
OR Klebsiella* OR Salmonell* OR Shigell* OR Yersinia*):ab,ti) AND ((travel* OR touris* OR turista OR aviation OR ‘air transport’ 
OR airport*):ab,ti) AND ((resistan* OR coloni* OR ((antibiotic* OR antimicrob*) NEAR/3 sensitivit*) OR susceptib* OR carriage* OR 
carrier*):ab,ti) 
Web of Science  TS = (((“Gram negative” OR Enterobacteri* OR (Enter* NEAR/1 bacteria*) OR Enterobacter* OR Escherichia* OR “e coli” 
OR Klebsiella* OR Salmonell* OR Shigell* OR Yersinia*)) AND ((travel* OR touris* OR turista OR aviation OR “air transport” OR airport*)) 
AND ((resistan* OR coloni* OR ((antibiotic* OR antimicrob*) NEAR/3 sensitivit*) OR susceptib* OR carriage* OR carrier*))) 
Scopus  TITLE-ABS-KEY(((“Gram negative” OR Enterobacteri* OR (Enter* W/1 bacteria*) OR Enterobacter* OR Escherichia* OR “e coli” 
OR Klebsiella* OR Salmonell* OR Shigell* OR Yersinia*)) AND ((travel* OR touris* OR turista OR aviation OR “air transport” OR airport*)) 
AND ((resistan* OR coloni* OR ((antibiotic* OR antimicrob*) W/3 sensitivit*) OR susceptib* OR carriage* OR carrier*))) 
PubMed  ((Gram negative[tiab] OR Enterobacteri*[tiab] OR Entero bacteria*[tiab] OR Enteric bacteria*[tiab] OR Enterobacter*[tiab] 
OR Escherichia*[tiab] OR e coli[tiab] OR Klebsiella*[tiab] OR Salmonell*[tiab] OR Shigell*[tiab] OR Yersinia*[tiab])) AND ((travel*[tiab] 
OR touris*[tiab] OR turista[tiab] OR aviation[tiab] OR air transport*[tiab] OR airport*[tiab])) AND ((resistan*[tiab] OR coloni*[tiab] OR 
((antibiotic*[tiab] OR antimicrob*[tiab]) AND sensitivit*[tiab]) OR susceptib*[tiab] OR carriage*[tiab] OR carrier*[tiab])) AND publisher[sb]
Google Scholar “Gram negative”|Enterobacteriaceae|Escherichia|Klebsiella|Salmonella|Shigella|Yersinia travel|traveller|tourist|tourism 
resistance|resistant|colonization|colonisation|susceptibility|carriage|carrier
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screening the abstracts, the full text of the articles was 
assessed for eligibility by the same two researchers 
and selected or rejected for inclusion in the system-
atic review. In case of disagreement a third researcher 
(A.V.) decided on inclusion.
Data collection process
The following data (if available) were extracted from 
each article: year of publication, country of the study, 
study period, study design, microorganism studied, 
study population, study size, age, sex, sample time 
before and after travel, duration of travel, travelling 
in pairs or groups, symptoms during travel, countries 
visited, MRE prevalence before travel, MRE prevalence 
after travel, MRE resistance acquired during travel, 
resistance to other antibiotic drugs of acquired MRE, 
risk factors for acquisition (among which travel to pre-
defined United Nations geographical regions: south-
ern Asia, Asia except southern Asia, Africa, South and 
Central America, North America, Europe and Oceania 
[14]), method of MRE susceptibility determination, 
phenotypic approaches, genotypic characterisation 
of post-travel MRE isolates, molecular typing of post-
travel MRE isolates, duration of MRE colonisation and 
MRE transmission to household contacts. To obtain 
missing data, authors of the articles were contacted.
Quality assessment
We assessed the methodological quality and the 
risk of bias in individual studies that may affect the 
cumulative evidence, using tools for assessing qual-
ity and susceptibility to bias in observational studies 
as recommended in the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) 
Statement [15,16].
Data synthesis and analysis
As a result of the design of the studies (cohort studies) 
and the heterogeneity in patient populations (e.g. trav-
ellers, healthcare workers and healthcare students), a 
formal meta-analysis was not possible. Therefore, the 
study results were summarised to describe the main 
outcomes of interest. The principle summary meas-
ure was percentage of MRE acquisition during travel, 
defined as ESBL-E or pAmp C-E. Furthermore, risk fac-
tors for acquisition of drug resistance were assessed. 
If possible, percentages not presented in the articles 
were calculated from the available data.
Results
Study selection
A total of 2,398 studies were identified through data-
base searching after duplicates had been removed 
(Figure). After screening of titles and summaries, 36 
articles were selected for full-text assessment. Eleven 
articles were included in the qualitative synthesis of 
the systematic review (see Figure for reasons for exclu-
sion) [17-27].
Study characteristics
Eleven prospective cohort studies, conducted in north-
ern and western Europe, Australia and the United 
States (US) were included [17-27]. The characteristics of 
these studies are shown in Table 1. Nine studies inves-
tigated travellers visiting a travel or vaccination clinic, 
one study hospital staff and contacts, and one study 
healthcare students working or studying abroad. The 
number of study participants ranged from 28 to 574. 
The median age of travellers in the individual studies 
varied between 25 and 66 years, with the youngest 
group being healthcare students. In all studies, the 
majority of travellers were female (range: 55–78%). The 
proportion of participants who were lost to follow up 
varied from 3.8% (4/106) [18] to 30% (12/40) [21]. The 
mean duration of travel was similar in all studies (14–
21 days). In the study by Angelin et al. on healthcare 
students, median length of stay was 45 days (range: 
13–365 days) [22]. In four studies, follow-up samples of 
MRE carriers were collected at six months after return-
ing from travel, and in one of these studies, samples 
were collected monthly in the first three months with 
further follow-up until 12 months after return [25]. Ten 
studies used a phenotypic method for susceptibility 
testing, with genotypic confirmation of ESBL positiv-
ity by PCR [17-22,24-27]. One study used a PCR-based 
approach [23]. In one study, only isolated E. coli were 
included, whereas the other studies included all iso-
lated Enterobacteriaceae, which mainly consisted of E. 
coli [17-27].
Acquisition of multidrug-resistant 
Enterobacteriaceae
Faecal carriage of MRE varied from 1 to 12% before 
travel and acquisition of MRE from 21% to 51% (Table 
2 [17-21,23-27]. 
In the study by Kuenzli et al. on travellers to the Indian 
subcontinent only, a much higher MRE acquisition rate 
of 69% was demonstrated [26]. The risk of acquisition 
of MRE varied with the geographical region (Table 3) 
[17-21,23-27]. Travel to southern Asia posed the highest 
risk (range: 29–88%), followed by other Asian coun-
tries (18–67%) and Northern Africa (range: 31–57%). 
Acquisition of MRE after travelling to sub-Saharan 
Africa (range: 0–49%) or South and Central America 
(range: 0–33%) was less frequent, and three studies 
did not observe any acquisition of MRE after travel to 
South or Central America (Table 3). Acquisition of MRE 
after travel to North America, Europe and Oceania was 
rare. Results of the genotypic characterisation of MRE 
isolated after travel are presented in Table 2, the major-
ity of the genes belonged to the CTX-M type.
Risk factors for acquisition of multidrug-
resistant Enterobacteriaceae
Besides travel destinations, other risk factors for 
acquiring MRE were age, use of antibiotics during travel 
(beta-lactam use) and gastroenteritis or other gastro-
intestinal symptoms (Table 2). The study of Kantele 
et al., designed to study these risk factors as primary 
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outcome, showed that travel diarrhoea (adjusted 
odds ratio (AOR) = 31.0; 95% confidence interval (CI): 
2.7–358.1)) and antibiotic therapy for travel diarrhoea 
(AOR = 3.0; 95% CI: 1.4–6.7) proved to be the most 
important risk factors for acquiring MRE [20]. In the 
study of Kuenzli et al. in which only travellers to south-
ern Asia were included, risk factors for MRE acquisition 
were length of stay, visit to family or friend and con-
sumption of ice cream or pastry (Table 2) [26]. Angelin 
et al. found a significant association for travel to the 
South-East Asia region (OR = 30; 95% CI: 6.3–147.2), 
and antibiotic treatment during travel (OR = 5; 95% 
CI: 1.1–26.2), but found no association with travellers’ 
diarrhoea or patient-related healthcare work [22]. 
Resistance of multidrug-resistant 
Enterobacteriaceae to other antibiotic drugs
Resistance of post-travel MRE isolates to various anti-
biotics was determined in nine studies (Table 4) [17-
19,21-24,26,27]. In the study by Wintersdorff et al., a 
PCR-based approach was used, therefore it was not 
possible to determine which microorganism carried 
the resistance genes [23]. The resistance data to other 
antibiotic drugs in the study by Kennedy et al. were not 
part of the publication, but were provided on request 
[18]. Antimicrobial resistance was high for ciprofloxa-
cin, varying from 31% to 57%, and for cotrimoxa-
zole, varying from 49% to 86% [17-19,21-24,26,27]. 
Aminoglycoside resistance was high for gentamicin 
(range: 17–50%) and tobramycin (range: 18–59%) and 
low for amikacin (range: 2–5%) [17-19,21-24,26,27]. 
Carbapenemase-producing Enterobacteriaceae were 
observed in four travellers who had all visited India 
(in the study by Ruppé et al., two OXA-181 and one 
New Delhi metallo-beta-lactamase 1 (NDM-1), and in 
the study by Kuenzli et al., one NDM-1 but this strain 
was not included in the resistance results) [25,26]. 
Resistance to nitrofurantoin, colistin and fosfomycin 
was only analysed in some of the studies (Table 4) 
[18,19,21-23,26].
Duration of multidrug-resistant 
Enterobacteriaceae carriage after return, risk 
factors for a long duration and rate of infection 
after travel
Five studies analysed MRE carriage six months after 
travel, and the persistence rate of acquired MRE 
after six months was 6–24% of travellers (Table 2) 
[17,18,24,25,27]. Ruppé et al. analysed MRE carriage 
one, two, three, six and twelve months after travel, 
showing persistence of carriage of an acquired MRE 
in 34, 19, 10, 5 and 2%, respectively [25]. Travellers 
to Asia showed longer carriage of MRE compared with 
other travel destinations. Carriage of multidrug-resist-
ant E. coli had a lower risk for prolonged carriage than 
other multidrug-resistant species. No other risk fac-
tors were found for prolonged carriage of MRE. Eight 
travellers in this study reported an episode of urinary 
tract infection after their return, but no microbiological 
data were available [25]. In the study by Tängdén et al., 
five of 21 travellers remained carriers of MRE after six 
months. However, none of these participants reported 
clinical infections [17]. In the study of Kennedy et al., 
one person developed a urinary tract infection with a 
travel-related organism [18]. Kantele et al. performed 
a one-year laboratory-based follow-up and did not find 
any clinical samples with MRE [20].
Rate of transmission to household members
Only one study screened household contacts for MRE 
after return of the index traveller. Household contacts 
were defined as persons who shared the same house-
hold with a participant on a regular basis. Two of 11 
contacts were found MRE-positive [24]. Both carried a 
different ESBL-producing E. coli based on multilocus 
sequence typing (MLST) than the associated traveller.
Limitations of the studies
The quality of the studies and the susceptibility of bias 
between the studies were assessed. In all but one study, 
participants constituted a non-random sample of the 
general travelling population [17-21,23-27]. However, 
Angelin et al. studied healthcare students working or 
studying abroad [22]. Studies were performed on three 
different continents. Travel destinations and travel 
behaviour may differ considerably between different 
nationalities and age groups. Including co-travellers, 
as done in all studies except Paltansing et al. and 
Ruppé et al., can result in similar travel behaviour and 
therefore, similar risk factors. Overall, the main out-
come was not influenced by recall or interviewer bias. 
For other outcomes such as risk factors, the risk of 
recall bias or interviewer bias was low because of the 
use of self-administered questionnaires.
Every study had participants lost to follow-up for 
post-travel stool samples and follow-up stool sam-
ples. Asymptomatic faecal carriage of MRE is probably 
not related to loss to follow-up, therefore, the risk of 
information bias is small. Ruppé et al. calculated post-
travel MRE carriage as those travellers with persisting 
MRE carriage divided by all travellers with MRE acqui-
sition plus all travellers without MRE post-travel [25]. 
However, travellers without MRE were not included in 
the follow-up. As a result, local MRE acquisition was 
not included in the calculated post-travel MRE car-
riage prevalence. Therefore the true prevalence can be 
assumed to be higher.
In five studies, travellers visited multiple regions or 
even continents during their trip [17-20,27]. In these 
travellers, it was not possible to attribute MRE prev-
alence or MRE acquisition to a certain geographi-
cal region. However, travellers in these studies were 
included in the MRE prevalence or MRE acquisition 
rates of more than one geographical region, which may 
have introduced information bias.
Seven studies used stool samples for detection of MRE 
[17,19-21,23,25,27] and three studies used rectal or 
perianal swabs for detection of MRE [18,24,26]. This 
might have influenced detection of MRE carriage. 
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Study 
Southern 
Asia  
% (ratio) 
Asia except 
southern Asia  
% (ratio) 
Northern Africa  
% (ratio) 
Sub-Saharan 
Africa  
% (ratio) 
South and 
Central America  
% (ratio) 
North 
America  
% (ratio) 
Europe  
 
% (ratio) 
Oceania  
 
% (ratio) 
Tängdén [17]a,b 78 (7/9)
29 
(10/34)
33 
(4/12) 4 (1/23)
0 
(0/7)
0 
(0/2)
13 
(2/16) -
Kennedy [18]a,c 57 (8/14)
25 
(21/85)
33 
(1/3)
0 
(0/2)
20 
(1/5)
20 
(2/10)
14 
(3/21)
0 
(0/2)
Östholm-Balkhed 
[19]a,b
71 
(10/14)
43 
(26/60) 57 (17/30)
21 
(15/71)
16 
(5/31)
0 
(0/15)
0 
(0/15) No data
Kantele [20]b,d 46 (28/61)
32 
(37/116)
67 
(2/3)
12 
(23/193)
0 
(0/40)
0 
(0/2)
0 
(0/15) No data
Weisenberg [21]b 29 (2/7)
25 
(1/4)
33 
(1/3)
13 
(1/8)
33 
(2/6) No data No data No data
Angelin [22] 63 (25/40)
67 
(6/9) No data
10 
(4/40)
0 
(0/5)
0 
(0/4) No data No data
von Wintersdorff 
[23]c
58 
(18/31)
20 
(6/29)
31 
(5/16)
29 
(5/17)
0 
(0/10) No data
17 
(1/6) No data 
Paltansing [24]b,e 72 (18/25) 41 (60/146)
40 
(4/10)
24 
(20/82)
15 
(9/60) No data No data No data
Ruppé [25]f 88 (53/60)
66 
(61/93) No data
49 
(89/182)
31 
(48/155) No data No data
0 
(0/2)
Kuenzli [26]b 69 No data No data No data No data No data No data No data
Lübbert [27]a,b 72 (13/18)g
33 
(24/73)g No data 
24 
(19/78)
8 
(6/78)
0 
(0/2)
20 
(2/10) No data
Table 3
Proportion of travellers who acquired multidrug-resistant Enterobacteriaceae, by travel destination (n = 11 studies)
MRE: multidrug-resistant Enterobacteriaceae.
a Travellers visiting more than one region are categorised in all the visited geographical regions. 
b Study reports data on MRE acquisition in travellers.
c Study reports data on MRE prevalence in travellers.
d Travellers visiting more than one region are categorised in the geographical region with the longest stay for this study.
e One traveller who visited Iran is categorised in Asia instead of Southern Asia.
f 42 travellers visited more than one country in Asia and may be represented in more than one column in the Table; 28 of them acquired MRE. 
g Exact numbers unpublished.
Southern Asia: Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri Lanka.
Asia (without southern Asia): Armenia, Azerbaijan, Bahrain, Brunei, Cambodia, China, Cyprus, Georgia, Hong Kong, Indonesia, Iraq, Israel, 
Jordan, Japan, Kazakhstan, Kuwait, Kyrgyzstan, Laos, Lebanon, Mongolia, Malaysia, Myanmar, North Korea, Oman, Philippines, Qatar, 
Saudi Arabia, South Korea, Singapore, Palestine, Syria, Tajikistan, Thailand, Timor-Leste, Turkey, Turkmenistan, United Arab Emirates, 
Uzbekistan, Viet Nam, Yemen.
Northern Africa: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara.
Sub-Saharan Africa: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, 
Congo (Brazzaville), Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, 
Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Réunion, 
Rwanda, São Tomé and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, The Gambia, Togo, 
Uganda, Zambia, Zimbabwe.
South and Central America: Anguilla, Antigua and Barbuda, Argentina, Aruba, Bahamas, Barbados, Belize, Bolivia, Bonaire, Sint Eustatius 
and Saba, Brazil, British Virgin Islands, Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curaçao, Dominica, Dominican Republic, 
Ecuador, El Salvador, Falkland Islands, French Guiana, Grenada, Guadeloupe, Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, 
Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent and 
the Grenadines, Saint-Barthélemy, Sint Maarten, Suriname, Trinidad and Tobago, Turks and Caicos Islands, US Virgin Islands, Uruguay, 
Venezuela.
North America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States.
Europe: Åland Islands, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Channel Islands, Croatia, Czech 
Republic, Denmark, Estonia, Faeroe Islands, Finland, the former Yugoslav Republic of Macedonia, France, Germany, Gibraltar, Greece, 
the Holy See, Hungary, Iceland, Ireland, Isle of Man, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Monaco, Montenegro, 
Netherlands, Norway, Poland, Portugal, Moldova, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Svalbard and Jan Mayen, 
Sweden, Switzerland, Ukraine, United Kingdom.
Oceania: American Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Micronesia, Nauru, New 
Caledonia, New Zealand, Niue, Norfolk Island, Northern Mariana Islands, Palau, Papua New Guinea, Pitcairn Islands, Samoa, Solomon 
Islands, Tokelau, Tonga, Tuvalu, Vanuatu, Wallis and Futuna.
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Discussion
In this systematic review we found a high prevalence 
of faecal carriage of MRE after international travel. The 
highest prevalence of MRE was observed in isolates 
from travellers returning from southern Asia, with up 
to 88% acquisition of MRE. In addition to the antibi-
otics not effective against MRE, an alarmingly high 
prevalence of resistance to other commonly used anti-
biotics such as cotrimoxazole (49–86%), ciprofloxacin 
(31–57%) and aminoglycosides (gentamicin 17–71%) 
was observed in ESBL-positive isolates in travellers in 
all studies [17-27].
Returning international travellers with MRE may intro-
duce these microorganisms in their home countries. 
This may cause community-onset infections with MRE 
in patients without obvious risk factors transmitted by 
healthy carriers through food or person-to-person con-
tact [9]. Infections caused by MRE are associated with 
poorer outcome and a higher overall mortality rate than 
infections caused by susceptible bacteria [28]. In this 
review, all studies showed an increased prevalence of 
faecal carriage of ESBL after international travel. It is 
not possible to evaluate the proportion of travellers 
who will develop infection with these resistant bacte-
ria. However, studies have demonstrated that interna-
tional travel is a risk factor associated with developing 
an infection with an MRE [11,12,29].
Many countries have infection prevention and con-
trol guidelines to detect and treat multidrug-resistant 
organisms (MDROs) including MRE [30]. In countries 
with low prevalence of MRE, infection prevention and 
control guidelines mainly include strategies for early 
identification and isolation of patients recently hos-
pitalised in foreign hospitals [30,31]. Patients with 
a recent history of travel to MRE-endemic areas but 
not admitted to healthcare facilities abroad are not 
normally considered at risk for carriage of MDROs. 
However, in hospitalised patients with a recent history 
of travel, increased rates of carriage of MRE have been 
observed [10,29,30]. Physicians should be aware of the 
risk that patients with recent travel to areas with high 
faecal carriage of MRE, as presented in this review, 
may introduce MRE to the hospital. Routine screening 
Study Ciprofloxacin % (ratio) 
Cotrimoxazole 
% (ratio) 
Gentamicin  
% (ratio) 
Amikacin  
% (ratio) 
Tobramycin  
% (ratio) 
Carbapenem  
% (ratio) 
Nitrofurantoin  
% (ratio) 
Colistin  
% (ratio) 
Fosfomycin  
% (ratio) 
Tängdén [17]a 50b 79 (19/24) 45
b No data 38b 0b 0b No data 8.0b
Kennedy [18]c 55 (12/22) No data
50 
(11/22) No data
59 
(13/22) No data No data No data No data
Östholm-
Balkhed [19]a
31 
(36/116)
70 
(81/116)
41 
(48/116)
2 
(2/116)
46 
(53/116)
0 
(0/116)
7 
(8/116) No data
3 
(3/116)
Kantele [20] No data No data No data No data No data No data No data No data No data
Weisenberg 
[21]a
43 
(3/7)d
86 
(6/7)
43 
(3/7) No data No data
0 
(0/7) No data No data No data
Angelin [22] 57 (28/49) 75
b 30b No data No data 0 (0/49) 2
b No data No data
von 
Wintersdorff 
[23]e
37 
(45/122) 
qnrB 
56 
(68/122) 
qnrS
No data
71 
(86/122) 
aac(6’)-
aph(2’’)
71 
(86/122) 
aac(6’)-
aph(2’’)
71 
(86/122) 
aac(6’)-
aph(2’’)
0 
(0/122) 
blaNDM
No data No data No data
Paltansing 
[24]f 36 67 35 No data 37 0 29 0 No data
Ruppé [25] No data No data No data No data No data 0.6 (3/526)g No data No data No data
Kuenzli [26]a 41 (64/157)
49 
(77/157) No data
5 
(7/157)
18 
(28/157)
0 
(0/157)
2 
(3/157)
0 
(0/157)
0.6 
(1/157)
Lübbert [27]a 43 (25/58)
83 
(48/58)
17 
(10/58) 2
b 22b 0b No data 0b 16b
Table 4
Antibiotic drug resistance of newly acquired multidrug-resistant Enterobacteriaceae in travellers (n = 11 studies)
bla: beta-lactamase; CPE: carbapenemase-producing Enterobacteriaceae; ESBL: extended-spectrum beta-lactamase.
a Resistance among acquired ESBL-positive isolates detected in post-travel samples.
b Data extracted from bar chart, exact numbers unpublished.
c Resistance among prevalent ESBL-positive isolates detected in post-travel samples.
d Percentage of susceptibility to levofloxacin.
e Prevalent resistance genes in faecal samples post-travel.
f Resistance among prevalent ESBL-positive isolates detected in pre- and post-travel samples.
g Three acquired CPE detected in post-travel samples. 
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for MRE seems indicated in such patients. Furthermore, 
empiric antibiotic therapy may fail when an infection 
by MRE is not taken into account. Therefore, careful 
recording of travel history needs to be incorporated in 
each patient evaluation. As shown in this review, there 
is also an increased risk of resistance against other 
antibiotics in travellers with MRE carriage. It is likely 
that this is caused by multiple genes, each encoding 
resistance to different classes of antibiotics, which 
are often found on the same bacterial mobile genetic 
element (e.g. a plasmid) [32]. As a result, other antibi-
otics, such as aminoglycosides, will also fail in many 
MRE-positive patients. 
Of all MDROs, emergence of CPE is most worrisome 
because of the limited treatment options for these infec-
tions. NDM-1-producing Enterobacteriaceae have been 
found in environmental samples in endemic regions 
[33]. CPE (NDM-1) in patients from the United Kingdom 
with a recent history of travelling or medical tourism 
to India are already an important public health prob-
lem [8]. Case reports have also demonstrated acquisi-
tion of CPE in travellers without contact with medical 
healthcare facilities [34,35]. In this review, four travel-
lers from India were carrying a carbapenemase-produc-
ing E. coli [25,26]. Preliminary results of the Carriage Of 
Multiresistant Bacteria After Travel (COMBAT) study, a 
large-scale multicentre longitudinal cohort study con-
ducted in the Netherlands among 2001 travellers, show 
acquisition of CPE in four travellers [36].
There are, besides the destination of travel, additional 
risk factors for acquiring MRE during travel. Antibiotic 
therapy was found to increase the risk [20,22]. In five 
studies, traveller’s diarrhoea or gastroenteritis were 
associated with an increased risk of MRE acquisition 
during travel [17-20,25]. Also, in one study, meticulous 
hand hygiene or strict consumption of bottled water 
did not lower the risk of acquiring MRE [22]. Therefore, 
it is not clear whether hygiene-related travel advice will 
decrease faecal carriage of MRE. Surprisingly, health-
care-related activities did not pose an increased risk of 
acquiring MRE in one study [22].
MRE and CPE could also be carried by food. 
International spread of these bacteria by food supply 
has been reported [37]. In this review, only one study 
showed that food consumption (ice cream and pas-
try) was associated with MRE carriage in travellers to 
southern Asia, whereas most of the studies did not 
focus on dietary patterns during travel.
One limitation of this review is the recruitment of trav-
ellers from travel clinics only, resulting in inclusion of 
very few travellers with European destinations. Some 
European countries such as Greece and Cyprus are also 
endemic for MRE and popular travel destinations [34]. 
In addition, travellers visiting their country of origin, 
especially Morocco and Turkey usually do not ask for 
a pre-travel consultation, although these countries are 
endemic for MRE and CPE [34]. It is not clear whether 
not including these patients may have led to an under- 
or overestimation of MRE acquisition.
Another limitation is the lack of sufficient data regard-
ing the duration of carriage and the transmission 
among non-travelling household members. The study 
by Ruppé et al. suggests that three months after 
return, MRE carriage is comparable with the baseline 
prevalence before travelling. However, the study did 
not include baseline prevalence in the follow-up. The 
COMBAT study will address some of these questions 
[38].
Conclusion
International travel is a major risk factor for acquisition 
of MRE. This risk is particularly high after travelling 
to (southern) Asia and in persons with travel-related 
diarrhoea and antibiotic use. Carriage of MRE-positive 
isolates is also associated with a high risk of resist-
ance to ciprofloxacin, cotrimoxazole and aminoglyco-
sides. Further research is needed to assess duration 
of carriage, spread to household contacts and whether 
introduction of MRE results in an increase of MRE infec-
tions. Our results, combined with the worldwide emer-
gence of CPE, further stress the importance of infection 
prevention and control guidelines.
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